{"entity":{"id":"nct03736889","kind":"trial","name":"Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors","aka":[],"tldr":"A phase 2 trial of Tislelizumab in advanced solid tumours, run by BeiGene, now recruiting.","summary":"Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors is a phase 2 interventional study registered as NCT03736889 by BeiGene, with 200 participants planned, started 2018-09-19 and due to reach its primary completion in 2026-11. Interventions recorded: Tislelizumab (BGB-A317).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03736889","url":"https://clinicaltrials.gov/study/NCT03736889"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["tislelizumab"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03736889","phase":"2","setting":"A Single-Arm, Multi-Center, Open-Label, Phase 2 Study to Evaluate Efficacy and Safety of Tislelizumab (BGB-A317), an Anti-PD-1 Monoclonal Antibody, as Monotherapy in Patients With Previously-Treated Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors","sponsor":"BeiGene","participation":[{"nct":"NCT03736889","source":"https://clinicaltrials.gov/study/NCT03736889","fetchedAt":"2026-10-07T16:53:07.935Z","studySha256":"28dc2db3ce9c0ec7211909e5a03c08acd9bba751c13a0bd11d983cb9e5a57497","overallStatus":"RECRUITING","lastUpdatePosted":"2026-07-10","leadSponsor":"BeiGene","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":200,"enrolmentType":"ESTIMATED","siteCount":30,"recruitingSiteCount":5,"countries":["China"]}],"started":"2018-09-19","startedType":"actual","enrolled":200,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03736889/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}]}}